EMEA-002405-PIP01-18 - paediatric investigation plan

Avadomide
PIPHuman

Key facts

Active Substance
Avadomide
Therapeutic area
Oncology
Decision number
P/0379/2018
PIP number
EMEA-002405-PIP01-18
Pharmaceutical form(s)
Capsule, hard
Condition(s) / indication(s)
Treatment of mature B-cell neoplasms
Route(s) of administration
Oral use
Contact for public enquiries

Celgene Europe Limited
Tel.  +41 327298500
E-mail: medinfo.intl@celgene.com

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date

Decision

Share this page